Cargando…
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management
The application of artificial intelligence (AI) to the electrocardiogram (ECG), a ubiquitous and standardized test, is an example of the ongoing transformative effect of AI on cardiovascular medicine. Although the ECG has long offered valuable insights into cardiac and non-cardiac health and disease...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848866/ https://www.ncbi.nlm.nih.gov/pubmed/33526938 http://dx.doi.org/10.1038/s41569-020-00503-2 |
_version_ | 1783645217699659776 |
---|---|
author | Siontis, Konstantinos C. Noseworthy, Peter A. Attia, Zachi I. Friedman, Paul A. |
author_facet | Siontis, Konstantinos C. Noseworthy, Peter A. Attia, Zachi I. Friedman, Paul A. |
author_sort | Siontis, Konstantinos C. |
collection | PubMed |
description | The application of artificial intelligence (AI) to the electrocardiogram (ECG), a ubiquitous and standardized test, is an example of the ongoing transformative effect of AI on cardiovascular medicine. Although the ECG has long offered valuable insights into cardiac and non-cardiac health and disease, its interpretation requires considerable human expertise. Advanced AI methods, such as deep-learning convolutional neural networks, have enabled rapid, human-like interpretation of the ECG, while signals and patterns largely unrecognizable to human interpreters can be detected by multilayer AI networks with precision, making the ECG a powerful, non-invasive biomarker. Large sets of digital ECGs linked to rich clinical data have been used to develop AI models for the detection of left ventricular dysfunction, silent (previously undocumented and asymptomatic) atrial fibrillation and hypertrophic cardiomyopathy, as well as the determination of a person’s age, sex and race, among other phenotypes. The clinical and population-level implications of AI-based ECG phenotyping continue to emerge, particularly with the rapid rise in the availability of mobile and wearable ECG technologies. In this Review, we summarize the current and future state of the AI-enhanced ECG in the detection of cardiovascular disease in at-risk populations, discuss its implications for clinical decision-making in patients with cardiovascular disease and critically appraise potential limitations and unknowns. |
format | Online Article Text |
id | pubmed-7848866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78488662021-02-01 Artificial intelligence-enhanced electrocardiography in cardiovascular disease management Siontis, Konstantinos C. Noseworthy, Peter A. Attia, Zachi I. Friedman, Paul A. Nat Rev Cardiol Review Article The application of artificial intelligence (AI) to the electrocardiogram (ECG), a ubiquitous and standardized test, is an example of the ongoing transformative effect of AI on cardiovascular medicine. Although the ECG has long offered valuable insights into cardiac and non-cardiac health and disease, its interpretation requires considerable human expertise. Advanced AI methods, such as deep-learning convolutional neural networks, have enabled rapid, human-like interpretation of the ECG, while signals and patterns largely unrecognizable to human interpreters can be detected by multilayer AI networks with precision, making the ECG a powerful, non-invasive biomarker. Large sets of digital ECGs linked to rich clinical data have been used to develop AI models for the detection of left ventricular dysfunction, silent (previously undocumented and asymptomatic) atrial fibrillation and hypertrophic cardiomyopathy, as well as the determination of a person’s age, sex and race, among other phenotypes. The clinical and population-level implications of AI-based ECG phenotyping continue to emerge, particularly with the rapid rise in the availability of mobile and wearable ECG technologies. In this Review, we summarize the current and future state of the AI-enhanced ECG in the detection of cardiovascular disease in at-risk populations, discuss its implications for clinical decision-making in patients with cardiovascular disease and critically appraise potential limitations and unknowns. Nature Publishing Group UK 2021-02-01 2021 /pmc/articles/PMC7848866/ /pubmed/33526938 http://dx.doi.org/10.1038/s41569-020-00503-2 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Siontis, Konstantinos C. Noseworthy, Peter A. Attia, Zachi I. Friedman, Paul A. Artificial intelligence-enhanced electrocardiography in cardiovascular disease management |
title | Artificial intelligence-enhanced electrocardiography in cardiovascular disease management |
title_full | Artificial intelligence-enhanced electrocardiography in cardiovascular disease management |
title_fullStr | Artificial intelligence-enhanced electrocardiography in cardiovascular disease management |
title_full_unstemmed | Artificial intelligence-enhanced electrocardiography in cardiovascular disease management |
title_short | Artificial intelligence-enhanced electrocardiography in cardiovascular disease management |
title_sort | artificial intelligence-enhanced electrocardiography in cardiovascular disease management |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848866/ https://www.ncbi.nlm.nih.gov/pubmed/33526938 http://dx.doi.org/10.1038/s41569-020-00503-2 |
work_keys_str_mv | AT siontiskonstantinosc artificialintelligenceenhancedelectrocardiographyincardiovasculardiseasemanagement AT noseworthypetera artificialintelligenceenhancedelectrocardiographyincardiovasculardiseasemanagement AT attiazachii artificialintelligenceenhancedelectrocardiographyincardiovasculardiseasemanagement AT friedmanpaula artificialintelligenceenhancedelectrocardiographyincardiovasculardiseasemanagement |